Actively Recruiting
Long-Term Observational Study of Teplizumab Treatment Outcomes in Stage 2 Type 1 Diabetes
Led by Sanofi · Updated on 2026-08-25
1000
Participants Needed
10
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the long-term outcomes of teplizumab treatment in people with Stage 2 Type 1 Diabetes T1D to see if it delays the onset of Stage 3 T1D. This observational, prospective cohort study will monitor participants who receive teplizumab as part of their usual clinical care across multiple sites. The study also assesses patient-reported outcomes to understand the emotional and psychosocial impact of T1D and its treatment. Participants treated with teplizumab in routine care will be followed for up to 10 years, depending on when they start the study after their initial infusion. The study does not provide any treatments but observes how teplizumab is used in real-world practice. It will track various health measures, including glycemic control, adverse events, diabetes-related complications, and quality of life changes over time. Throughout the study, participants will have assessments to measure blood sugar control using different tests and devices, report any adverse events, and complete questionnaires about their emotional well-being. Researchers will measure the time from the start of teplizumab infusion to the development of Stage 3 T1D and monitor hospital visits related to diabetes. The total study duration for each participant may last up to 10 years, offering a detailed view of teplizumabs effects in everyday clinical settings.
CONDITIONS
Brief Title
Long-Term Outcomes of Teplizumab in Routine Clinical Care
Research Team
T
Trial Transparency email recommended (Toll free for US & Canada)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here